Fundamental Analysis of MEI Pharma Inc - Growth / Value Index


MEIP - Valuation Highlights

Valuation Analysis

   Price to Earning Ratio is 0.805 and EV to EBITDA is 0.236 suggesting company is undervalued.
   Price to Book Ratio is 0.420 indicating that it is undervalued.
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 0.802 -0.659 -82.13 %
Price to Book 0.418 0.852 126.66 % 0.411
Price to Sales 0.314 0.430 -11.22 %
Enterprise Value to EBITDA Multiple 0.234 -0.150 -66.72 %


MEIP - Profitability Highlights

Profitability Analysis

   Earning Yield of 124.22 %
   During the past twelve months, the company has given a strong Return On Equity of 52.13%
   During the past twelve months, the company has given a strong Return On Asset of 25.84%
   During the past twelve months, the company has given a strong Net Margin of 39.18%
   All key Trailing Twelve Months Margin growing by 15 %
   Piotroski F Score - Very Poor Value of 1.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 52.13 -129.30 -24.45 % -17.89
Return On Asset 25.84 -26.35 13.93 % -12.81
Net Profit Margin 39.18 -65.22 51.26 % 0
Operating Profit Margin 33.62 -75.31 59.40 % 0
EBITDA Margin 35.34 -75.31 43.08 % 0


Highlights
Market Cap20988.01 K
Enterprise Value5510.01 K
Price/Book TTM0.418
Outstanding Share6662.86 K
Float/ Outstanding Share74.16%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0.174
Peter Lynch Ratio0
Piotroski F Score1.00
Altman Z Score-4.32
Sloan Ratio-0.274
Peter Lynch Fair Value0


MEIP - Growth Highlights

Growth Analysis

   Tsr Growth Index - Excellent Score of 84.90
   Annual sales of the company is increased for three years in a row
   Quarterly sales in last 5 Quarter is trending down
   Company's Total Assets is Decreasing for last 3 years
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 66754.00 K 19.95 % %
Gross Profit 66583.00 K 19.95 % 1.18 %
EBITDA 23591.00 K 31.72 % 17.61 %
Net Profit 26155.00 K 41.53 % 17.50 %
EPS 3.93 45.09 % NA


MEIP - Stability Highlights

Stability Analysis

   Cash ratio of 4.95
   Tsr Stability Index - Poor Score of 30.36
   Altman Z Score of -4.32 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.058 248.97 % 0.0206
Cash Ratio 4.95 -21.04 %
Quick Ratio 0 0 % 6.17
Shareholders Equity 20.38 -30.84 %
Debt to EBITDA -0.0388 -140.12 %


Historical Valuation Ratios of MEI Pharma Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of MEI Pharma Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of MEI Pharma Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of MEI Pharma Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)